Plus Therapeutics Analyst Revisions: Shifting Targets and High Growth Story

Analysts covering Plus Therapeutics have reset their price target assumptions, cutting the modeled fair value from $9.67 to $5.50 while nudging the discount rate higher. Revenue growth expectations remain high at 99.05%, keeping a high growth story in play despite recalibrated implied upside. Lake Street initiated coverage with a bullish stance, while Maxim and H.C. Wainwright lowered their price targets, indicating caution about the company's valuation.